Table 3 ADSC therapies for AAA models
Disease model | Cell type | Delivery method | Day(s) of ADSC delivery | Day(s) of harvest | Output measurement | Reference |
|---|---|---|---|---|---|---|
Elastase model in mice | Mouse ADSCs | Subcutaneous microport delivery | Day 5 | Days 5, 14 | Cell treated aneurysms had less dilation and intact elastin | |
Elastase model in mice | Human ADSCs | IV injection | Day 0 | Days 1, 4, 7, 14 | ADSCs suppressed AA expansion through 14 days, increased Treg, decreased levels of CD115 + CXCR1 − LY6C+ monocytes, | |
Calcium chloride model in rats | Rat ADSCs | IA injection | Day 0 | Day 28 | In vivo ADSC group significantly increased elastin production, decreased MMP2/9 | |
Dacron patches in pigs | Pig ADSCs | Catheter scaffold with fibrin sealant | Day 0 | Days 1, 7, 21, 35, 49, 63 | MSC group has lower inflammation reaction, and observed GFP marked cells up to 3 weeks | |
Calcium chloride and elastase model in rats | Rat ADSCs | Cell-seeded scaffold | Day 0 | Day 14 | ADSC group diameter didn’t differ significantly from the sham group and had better looking elastin than the aneurysm controls. The cell group had a significantly higher number of VSMCs in the vessel and lower levels of macrophages | |
Elastase model in rats | Rat ADSCs | IV injection | Day 0 | Day 28 | No significant difference between cell and control group in neutrophil or macrophage infiltration, elastin content, or aortic diameter. | |
Elastase + collagenase injected in pigs | Human adipose-derived MSCs | GelFoam sponge directly applied | Day 0 | Day 21 | Reduced aortic dilation, higher preservation of elastin, preserved SMCs, increased VEGF, TIMP1, and TIMP3, and Young’s elastic modulus. Higher collagen content, alpha smooth muscle action, and elastin perturbation than untreated. |
